Codexis (CDXS) Projected to Post Quarterly Earnings on Thursday

Codexis (NASDAQ:CDXS) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $35.8340 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Codexis Stock Down 3.3%

CDXS opened at $1.17 on Thursday. Codexis has a 52 week low of $1.12 and a 52 week high of $4.46. The business has a 50 day moving average price of $1.53 and a two-hundred day moving average price of $2.08. The company has a quick ratio of 4.02, a current ratio of 4.12 and a debt-to-equity ratio of 1.03. The company has a market cap of $105.67 million, a PE ratio of -1.54 and a beta of 2.46.

Analysts Set New Price Targets

CDXS has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Codexis in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of Codexis from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Codexis has a consensus rating of “Sell”.

Institutional Investors Weigh In On Codexis

A number of large investors have recently bought and sold shares of CDXS. State of Wyoming purchased a new position in shares of Codexis in the 2nd quarter worth about $25,000. Victory Capital Management Inc. purchased a new position in Codexis in the third quarter valued at approximately $25,000. CIBC Bancorp USA Inc. acquired a new position in Codexis during the third quarter valued at approximately $26,000. BNP Paribas Financial Markets grew its stake in Codexis by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 16,608 shares of the biotechnology company’s stock worth $41,000 after buying an additional 8,038 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Codexis in the fourth quarter worth $45,000. Institutional investors and hedge funds own 78.54% of the company’s stock.

About Codexis

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.